Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder

Neuropsychopharmacology

Volumn 14, Issue 2, 1996, Pages 125-137

  Castellanos, F Xavier ^a   Elia, Josephine ^b   Kruesi, Markus J P ^c   Marsh, Wendy L ^a   Gulotta, Charles S ^d   Potter, William Z ^a   Ritchie, Gail F ^a   Hamburger, Susan D ^a   Rapoport, Judith L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Analeptics; Attention deficit disorder with hyperactivity; Cerebrospinal fluid; Drug effects; Homovanillic acid; Psychostimulants

Indexed keywords

DEXAMPHETAMINE; HOMOVANILLIC ACID; METHYLPHENIDATE; PEMOLINE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HYPERACTIVITY; LUMBAR PUNCTURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030019923     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00077-Q     Document Type: Article

References (97)

1. Achenbach T, Edelbrock C (1983): Manual for the Child Behavior Checklist and Revised Child Behavior Profile. University of Vermont, Burlington, VT, Department of Psychiatry
2. Amin F, Davidson M, David KL (1992): Homovanillic acid in clinical research: A review of methodology. Schizophr Bull 18:123-148
3. Amin K, Douglas VT, Mendelson MJ, Dufresne J (1993): Separable/integral classification by hyperactive and normal children. Dev Psychopathol 5:415-431
4. Anderson GM, Riddle MA, Hoder EL, Feibel FC, Shaywitz BA, Cohen DJ (1988): The ontogeny of 3,4-dihydroxyphenylacetic acid in human cerebrospinal fluid. J Neurol Neurosurg Psychiatry 51:1,100-1,102
5. Arnold LE, Stoff DM, Cook E, Jr., Cohen DJ, Kruesi M, Wright C, Hattab J, Graham P, Zametkin A, Castellanos FX, McMahon W, Leckman JF (1995): Ethical issues in biological mental health research with children & adolescents. J. Am Acad Child Adolesc Psychiatry 34:929-939
6. 2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology (Berl) 108: 159-169
7. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS (1989): A double-blind, placebo-controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784
8. Blennow K, Wallin A, Gottfries CG, Mansson JE, Svennerholm L (1993): Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm Park Dis Dement Sect 5:5-15
9. Bonadio WA, Smith DS, Metrou M, Dewitz B (1988): Estimating lumbar-puncture depth in children [letter]. N Engl J Med 319:952-953
10. Borcherding BG, Keysor CS, Cooper TB, Rapoport JL (1989): Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 2:255-263
11. Braestrup C, Scheel-Kruger J (1976): Methylphenidate-like effects of the new antidepressant drug nomifensine (HOE 984). Eur J Pharmacol 38:305-312
12. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973): Dopaminergic neurons: Effects of antipsychotic drugs and amphetamines on single cell activity. J Pharmacol Exp Ther 185:560-571
13. Castellanos FX, Elia J, Kruesi MJ, Gulotta CS, Mefford IN, Potter WZ, Ritchie GF, Rapoport JL (1994): Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res 52:305-316
14. Chaouloff F, Laude D, Guezennec Y, Elghozi JL (1986): Motor activity increases tryptophan, 5-hydroxyindoleacetic acid, and homovanillic acid in ventricular cerebrospinal fluid of the conscious rat. J Neurochem 46:1,313-1,316
15. Chelune GJ, Ferguson W, Koon R, Dickey TO (1986): Frontal lobe disinhibition in attention deficit disorder. Child Psychiatry Hum Dev 16:221-234
16. Cohen DJ, Shaywitz BA, Young JG, Bowers MB, Jr (1980): Cerebrospinal fluid monoamine metabolites in neuropsychiatric disorders of childhood. In Wood JH (ed), Neurobiology of Cerebrospinal Fluid. New York, Plenum, pp 665-683
17. Commissiong JW (1985): Monoamine metabolites: Their relationship and lack of relationship to monoaminergic neuronal activity. Biochem Pharmacol 34:1,127-1,131
18. Cowdry RW, Ebert MH, van Kammen DP, Post RM, Goodwin FK (1983): Cerebrospinal fluid probenecid studies: A reinterpretation. Biol Psychiatry 18:1,287-1,299
19. Creese I (ed), (1983): Stimulants: Neurochemical, Behavioral, and Clinical Perspectives. New York, Raven
20. Donnelly M, Zametkin AJ, Rapoport JL, Ismond DR, Weingartner H, Lane E, Oliver J, Linnoila M, Potter WZ (1986): Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 39:72-81
21. Donnelly M, Rapoport JL, Potter WZ, Oliver J, Keysor CS, Murphy DL (1989): Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Arch Gen Psychiatry 46:205-212
22. 2 dopamine autoreceptor selective drugs: Do they really exist? Life Sci, 47:361-376
23. Duteil J, de Sereville JE, Multon MF, Pessonnier J, Rambert FA (1987): [Stereotyped movements and substantia nigra-corpus striatum dopaminergic function in the rat: Action of methylphenidate after inhibition of monoamine oxidase]. Ann Pharm Fr 45:25-34
24. Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS (1990): Stimulant drug treatment of hyperactivity: Biochemical correlates. Clin Pharmacol Ther 48: 57-66
25. Elia J, Borcherding BG, Rapoport JL, Keysor CS (1991): Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatry Res 36:141-155
26. Everett GM (1981): Pemoline: A specific long-acting dopaminomimetic drug. In Gessa GL, Corsini GU (eds), Apomorphine and Other Dopaminomimetics, vol 1. Basic Pharmacology. New York, Raven, pp 261-263
27. Fung YK, Uretsky NJ (1982): The differential effects of amphetamine and methylphenidate on the biosynthesis of [3H]dopa from [3H]tyrosine in mouse striata in vivo. J Pharm Pharmacol 34:531-532
28. Garelis E, Young SN, Lal S, Sourkes TL (1974): Monoamine metabolites in lumbar CSF. The question of their origin in relation to clinical studies. Brain Res 79:1-8
29. Goyette CH, Conners CK, Ulrich RF (1978): Normative data on revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psychol 6:221-236
30. Gualtieri CT, Hicks RE (1985): Neuropharmacology of methylphenidate and a neural substrate for childhood hyperactivity. Psychiatr Clin North Am 8:875-892
31. Guy W (1976): Subject's treatment emergent symptom scale. In Guy W (ed), Assessment Manual for Psychopharmacology. Washington, DC, U.S. Government Printing Office, pp 347-350
32. Hart EL, Lahey BB, Loeber R, Appelgate B, Frick PJ (1995): Developmental change in attention-deficit/hyperactive disorder in boys: a four year longitudinal study. J Abnorm Child Psychol (in press)
33. Hedner J, Lundell KH, Breese GR, Mueller RA, Hedner T (1986): Developmental variations in CSF monoamine metabolites during childhood. Biol Neonate 49:190-197
34. Herjanic B, Campbell W (1977): Differentiating psychiatrically disturbed children on the basis of a structured interview. J Abnorm Child Psychol 5:127-134
35. Hsiao JK, Colison J, Bartko JJ, Doran AR, Konicki PE, Potter WZ, Pickar D (1993): Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 50:606-614
36. Hunt RD, Minderaa RB, Cohen DJ (1986): The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: A comparison with placebo and methylphenidate. Psychopharmacol Bull 22:229-236
37. Hunt RD, Arnsten AF, Asbell MD (1995): An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34: 50-54
38. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL (1993): Effect of neuroleptic medication on cerebrospinal fluid monomine metabolite concentrations in schizophrenia. Arch Gen Psychiatry 50:599-605
39. Karoum F (1983): Mass fragmentography in the analysis of biogenic amines. In Nagutsu T, Nagatsu I, Parvez H (eds), Methods in Biogenic Amine Research. New York, Elsevier, pp 237-255
40. Kinsbourne M (1973): Minimal brain dysfunction as a neurodevelopmental lag. Ann NY Acad Sci 205:268-273
41. Kopin IJ (1985): Catecholamine metabolism: Basic aspects and clinical significance. Pharmacol Rev 37:333-364
42. Kornetsky C (1970): Psychoactive drugs in the immature organism. Psychopharmacologia 17:105-136
43. Kostrzewa RM, Brus R, Kalbfleisch JH, Perry KW, Fuller RW (1994): Proposed animal model of attention deficit hyperactivity disorder. Brain Res Bull 34:161-167
44. Kruesi MJP, Swedo SE, Coffey ML, Hamburger SD, Leonard H, Rapoport JL (1988a): Objective and subjective side effects of research lumbar punctures in children and adolescents. Psychiatry Res 25:59-63
45. Kruesi MJP, Swedo SE, Hamburger SD, Potter WZ, Rapoport JL (1988b): Concentration gradient of CSF monoamine metabolites in children and adolescents. Biol Psychiatry 24:507-514
46. Kruesi MJP, Hibbs ED, Zahn TP, Keysor CS, Hamburger SD, Bartko JJ, Rapoport JL (1992): A 2-year prospective follow-up study of children and adolescents with disruptive behavior disorders. Arch Gen Psychiatry 49:429-435
47. Kuczenski R, Segal DS (1975): Differential effects of D-and L-amphetamine and methylphenidate on rat striatal dopamine biosynthesis. Eur J Pharmacol 30:244-251
48. Kuczenski R, Segal DS (1992): Regional norepinephrine response to amphetamine using dialysis: Comparison with caudate dopamine. Synapse 11:164-169
49. Leckman JF, Cohen DJ, Shaywitz BA, Caparulo BK, Heninger GR, Bowers MB, Jr. (1980): CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective. Arch Gen Psychiatry 37: 677-681
50. Levy F (1991): The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aus NZJ Psychiatry 25: 277-283
51. Lloyd HGE, Stone TW (1983): The effects of some CNS stimulants on dopamine and 5HT release from rat striatal slices. Br J Pharmacol 78:S93
52. McCracken JT (1991): A two-part model of stimulant action on attention-deficit hyperactivity disorder in children. J Neuropsychiatry 3:201-209
53. Meador-Woodruff JH, Damask SP, Watson SJ, Jr. (1994): Differential expression of autoreceptors in the ascending dopamine systems of the human brain. PNAS 91:8,297-8,301
54. Mefford, IN, Potter WZ (1989): A neuroanatomic and biochemical basis for attention deficit disorder with hyperactivity in children: A defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. Med Hypotheses 29:33-42
55. Molina VA, Orsingher OA (1981): Effects of Mg-pemoline on the central catecholaminergic system. Arch Int Pharmacodyn Ther 251:66-79
56. Nordin C, Siwers B, Bertilsson L (1982): Site of lumbar puncture influences levels of monoamine metabolites. Arch Gen Psychiatry 39:1,445
57. Patrick KS, Caldwell RW, Ferris RM, Breese GR (1987): Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241:152-158
58. Paulson PE, Robinson TE (1994): Relationship between circadian changes in spontaneous motor activity and dorsal versus ventral striatal dopamine neurotransmission assessed with on-line microdialysis. Behav Neurosci 108: 624-635
59. Pierce RC, Rebec GV (1995): Iontophoresis in the neostriatum of awake, unrestrained rats: differential effects of dopamine, glutamate, and ascorbate on motor-and non-motor-related neurons. Neuroscience 67:313-324
60. Porrino LJ, Rapoport JL, Behar D, Ismond DR, Bunney WE, Jr. (1983): A naturalistic assessment of the motor activity of hyperactive boys. II. Stimulant drug effects. Arch Gen Psychiatry 40:688-693
61. Post RM, Kotin J, Goodwin FK, Gordon EK (1973): Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Am J Psychiatry 130:67-72
62. Potter WZ, Manji HK (1993): Are monoamine metabolites in cerebrospinal fluid worth measuring? Arch Gen Psychiatry 50:653-656
63. Rapoport JL, Buchsbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ (1978): Dextroamphetamine: Cognitive and behavioral effects in normal prepubertal boys. Science 199:560-563
64. Rapport MD, DuPaul GJ, Stoner G, Jones TJ (1986): Comparing classroom and clinic measures of attention deficit disorder: Differential, idiosyncratic, and dose-response effects of methylphenidate. J Consult Clin Psychol 54: 334-341
65. Rebec GV, Segal DS (1978): Dose-dependent biphasic alterations in the spontaneous activity of neurons in the rat neostriatum produced by D-amphetamine and methylphenidate. Brain Res 150:353-366
66. Reimherr FW, Wender PH, Ebert MH, Wood DR (1984): Cerebrospinal fluid homovanillic acid and 5-hydroxyindoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Res 11:71-78
67. Riddle MA, Anderson GM, McIntosh S, Harcherik DF, Shaywitz BA, Cohen DJ (1986): Cerebrospinal fluid monoamine precursor and metabolite levels in children treated for leukemia: Age and sex effects and individual variability. Biol Psychiatry 21:69-83
68. Roeltgen DP, Schneider JS (1991): Chronic low-dose MPTP in nonhuman primates: A possible model for attention deficit disorder. J Ch Neurol 6:S82-S89
69. Rosvold HE, Mirsky AF, Sarason I, Bransome ED, Beck LH (1956): A continuous performance test of brain damage. J Consul Psychol 20:343-350
70. SAS Institute, I (1989): SAS Language and Procedures: Usage, version 6, ed 1. Cary, NC, SAS Institute
71. SAS Institute, I (1990): SAS Procedures Guide, Version 6, ed 3. Cary, NC, SAS Institute
72. Schweri MM, Skolnick P, Rafferty MF, Rice KC, Janowsky AJ, Paul SM (1985): [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: Correlation with the stimulant properties of ritalinic acid esters. J. Neurochem 45:1,062-1,070
73. Schweri MM (1994): Mercuric chloride and p-chloromercuriphenylsulfonate exert a biphasic effect on the binding of the stimulant [3H]methylphenidate to the dopamine transporter. Synapse 16:188-194
74. Shaffer D, Gould MS, Brasie J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983): A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1,228-1,231
75. Shaywitz BA, Cohen DJ, Bowers MB (1977): CSF amine metabolites in children with minimal brain dysfunction: Evidence for alteration of brain dopamine - a preliminary report. J Pediatr 90:67-71
76. Shaywitz BA, Klopper JH, Gordon JW (1978): Methylphenidate in 6-hydroxydopamine-treated developing rat pups. Effects on activity and maze performance. Arch Neurol 35:463-469
77. Shaywitz BA, Cohen DJ, Leckman JF, Young JG, Bowers MB, Jr. (1980): Ontogeny of dopamine and serotonin metabolites in the cerebrospinal fluid of children with neurologic disorders. Dev Med Child Neurol 22:748-754
78. Shaywitz SE, Cohen DJ, Shaywitz BA (1978): The biochemical basis of minimal brain dysfunction. J Pediatr 92: 179-187
79. Shekim WO, Sinclair E, Glaser R, Horwitz E, Javaid J, Bylund DB (1987): Norepinephrine and dopamine metabolites and educational variables in boys with attention deficit disorder and hyperactivity. J Ch Neurol 2:50-56
80. Shenker A (1992): The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: Focus on catecholamine receptor pharmacology. Adv Pediatr 39: 337-382
81. Shetty T, Chase TN (1976): Central monoamines and hyperkinesis of childhood. Neurology 26:1,000-1,006
82. Sjöström R, Ekstedt J, Anggard E (1975): Concentration gradients of monoamine metabolites in human cerebrospinal fluid. J Neurol Neurosurg Psychiatry 38:666-668
83. Solanto MV (1986): Behavioral effects of low-dose methylphenidate in childhood attention deficit disorder: Implications for a mechanism of stimulant drug action. J Am Acad Child Psychiatry 25:96-101
84. Stern RG, Kahn RS, Davidson M (1993): Predictors of response to neuroleptic treatment in shizophrenia. Psychiatr Clin North Am 16:313-338
85. Tagliamonte A, Tagliamonte P (1971): Stimulation of brain dopamine turnover by magnesium pemoline (MgP). Fed Proc 30:223
86. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey S, Ashby C, Lieberman J, Hitzemann R, Wolf AP (1995): Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry 52:456-463
87. Wechsler, D (1974): Manual for the Wechsler Intelligence Scale for Children - Revised. New York, The Psychological Corporation
88. Wender PH (1973): Some speculations concerning a possible biochemical basis of minimal brain dysfunction. Ann NY Acad Sci 205:81-28
89. Werry JS, Sprague RL, Cohen MN (1975): Conners' Teacher Rating Scale for use in drug studies with children - an empirical study. J Abnorm Child Psychol 3:217-229
90. Westerink BH, Kikkert RJ (1986): Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J Neurochem 46:1,145-1,152
91. Wiener JN (ed), (1995): Diagnosis and Psychopharmacology of Child and Adolescent Disorders, ed 2. New York, John Wiley & Sons, Inc.
92. Woodcock RW, Johnson BB (1977): Woodcock-Johnson Psychoeducational Battery. Allen, TX, DLM Teaching Resources
93. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Karoum F, Potter WZ, Ismond D (1985): Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatry 42:969-973
94. Zametkin AJ, Karoum F, Linnoila M, Rapoport JL, Brown GL, Chuang LW, Wyatt RJ (1985a): Stimulants, urinary catecholamines, and indoleamines in hyperactivity. Arch Gen Psychiatry 42:251-255
95. Zametkin AJ, Hamburger SD (1988): The effect of methylphenidate on urinary catecholamine excretion in hyperactivity: A partial replication. Biol Psychiatry 23:350-356
96. Zametkin AJ, Rapoport JL (1987): Noradrenergic hypothesis of attention deficit disorder with hyperactivity: A critical review. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven, pp 837-842
97. Ziegler MG, Lake CR, Wood JH, Ebert MH (1980): Norepinephrine in cerebrospinal fluid. In Wood JH (ed), Neurobiology of Cerebrospinal Fluid. New York, Plenum, pp 141-151